Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. PROGRAM DESCRIPTION CARDIOVASCULAR FELLOWSHIP HARTFORD HOSPITAL/UNIVERSITY OF CONNECTICUT Program Director: Gary V. Heller, MD, Ph.D. Associate Directors: Donna M. Polk, MD, MPH Justin B. Lundbye, MD 80 Seymour Street, P.O. Box 5037 Hartford, CT 06102-5037 Fellowship Coordinator: Betty Doucette Director, Cardiology: Paul D. Thompson, MD Associate Directors, Cardiology: Gary V. Heller, MD, Ph.D. Jeffrey Kluger, MD Full-Time Faculty: Paul D. Thompson, MD Gary V. Heller, MD, Ph.D. Christopher Clyne, MD Jeffrey Kluger, MD Francis J. Kiernan, MD Justin B. Lundbye, MD Donna M. Polk, MD Joseph Radojevic, M.D. Detlef Wencker, MD David I. Silverman, MD Steven Zweibel, MD CLINICAL FACULTY: Interventional Cardiology Francis J. Kiernan, MD, Director Jeffrey Hirst, MD Charles A. Primiano, MD Daniel Fram, MD Raymond G. McKay, MD Joseph Mitchel, DO Echocardiography David I. Silverman, MD Heart Rhythm Management & Interventional Electrophysiology Jeffrey Kluger, MD, Director Christopher Clyne, MD, Director, Interventional Electrophysiology Steven Zweibel, MD, Director, Electrophysiology Nuclear Cardiology Exercise Laboratory Gary V. Heller, MD, Ph.D., Director Charles A. Primiano, MD, Director Preventive Cardiology Coronary Intensive Care Unit Donna M. Polk, MD, MPH, Director Justin B. Lundbye, MD, Director Ellen Dornelas, Ph.D. Heart Failure Services Detlef Wencker, MD, Director Joseph Radojevic, M.D.
  2. 2. 2 Current Cardiovascular Fellows First Year Residency Srilatha Ayirala, MBBS Michigan State University Talhat Azemi, MD University of Connecticut Aravind Kokkirala, MBBS St. Luke’s-Roosevelt Hospital Raja Pullatt, MBBS University of Connecticut Second Year Steven Borer, DO University of Connecticut A. Farooq Iqtidar, MD Dartmouth-Hitchcock Medical Ctr Fawad A. Kazi, MD University of Connecticut Anuj R. Shah, MD University of Connecticut Third Year Peter Chien, MD Georgetown Amyn Malik, MD University of Minnesota Yaqoob A. Mohyuddin, MD University of Virginia Kyle Richards, MD University of Connecticut Arshad M. Yekta, MD Mt. Sinai Hospital, NY Non-Invasive Cardiology Fellows Osman Faheem, MBBS University of Connecticut Anupama Voodarla, MBBS Brooklyn Hospital Cardiology Attendings James Cardon, MD Anthony LaSala, MD David M. Casey, MD Reza Mansoor, MD James Dougherty, MD Bekir Melek, MD Brett Duncan, MD Kenneth Merkatz, MD Andrew Feingold, MD Dariush Owlia, MD Melissa Ferraro-Borgida, MD Lawrence Pareles, MD Carol Gemayel, MD Ronald Pariser, MD Steve Goldblatt, MD Asad Rizvi, MD John Granquist, MD Fred Rubin, MD Steve Horowitz, MD Donald Ruffett, MD James Kallal, MD Kevin Tally, MD Stephen Kastoff, MD Jeffrey Walden, MD General Description The Cardiovascular Disease Program at Hartford Hospital/University of Connecticut is a three-year program specifically designed to prepare cardiovascular fellows for the practice of Cardiology. While in the three-year program, fellows receive training in basic cardiovascular diseases, clinical cardiology, and subspecialty practices. This is accomplished in several ways including clinical rotations which allows exposure to cardiovascular related diseases and problems, didactic sessions covering basic mechanisms of cardiovascular diseases, dedicated research months and subspecialty rotations. During the clinical rotations, the cardiovascular disease fellow interviews, examines and formulates basic evaluations in patients with
  3. 3. 3 cardiovascular related illnesses. During subspecialty training, cardiovascular disease fellows are exposed to the practices of cardiac catheterization, preventive cardiology, arrhythmias, nuclear cardiology, echocardiography, cardiovascular surgery, pacemaker techniques and interventional electrophysiology. During the third year, the cardiovascular disease fellow chooses either an invasive or non-invasive track for additional training in one of those areas. At the completion of the cardiovascular disease program, the fellow is qualified to enter the practice of cardiovascular diseases either in the invasive, non-invasive or clinical areas. Although, not specifically part of the cardiovascular disease program, interested fellows may choose a fourth year subspecializing in various aspects of cardiology in hopes of pursuing an academic career. The Interventional Cardiology Program at Hartford Hospital is ACGME approved and is an option for further training. The research experience in the cardiovascular disease program is designed to allow the fellow ample exposure to the process of designing, performing data analysis, and manuscript preparation of a research project. Research is begun in the first year specifically to allow the cardiovascular disease fellow opportunity to gain skill and knowledge in the performance of cardiovascular disease research and to allow time for completion of study. The early exposure to research also allows the fellow the opportunity to evaluate the possibility of entering academic cardiology. Fellows engaged in research are expected to prepare results for abstract and manuscript submission. Local hospital funding is available for support of projects, and several attending physicians have national support for studies. Dr. Paul D. Thompson is supervisor of the research experience for the fellows. Fellowship Length and Rotations The University of Connecticut/Hartford Hospital Cardiovascular Disease Fellowship Program consists of a 3- year blend of Clinical Cardiology, subspecialty training, and research. Hartford Hospital is one of the largest cardiovascular volume hospitals in the New England area and exposes the fellows to a wide range of cases, which will be encountered in future cardiovascular practice. The 1st year is primarily clinical and includes the consultation service, coronary care unit, and subspecialties of arrhythmia, echocardiography, nuclear cardiology, cardiac catheterization, and preventive cardiology. One month is set aside for research. The duties of the fellows are to gain knowledge in the various subspecialties and how they interact with clinical cardiology. Early exposure to subspecialties that separates the cardiology fellow from their internal medicine background is a key component of the program prior to CICU and Consultation rotations.
  4. 4. 4 The 2nd year is a similar format to the 1st year rotations with the exception of 2 months of research and elective time. In the 2nd year the fellow has more in depth exposure to clinical cardiovascular medicine as well as each of the subspecialties, and assumes greater responsibilities. The 3rd year fellow can choose two pathways between invasive and non-invasive cardiology. If the fellow chooses the invasive pathway, 9 months are spent in the cardiac catheterization laboratory and 3 months in research. A non-invasive pathway includes rotations in nuclear cardiology, echocardiography, and 3 months of research, which can be tailored to the individual fellow needs. Conference Schedule The fellows attend daily conferences, which include non-invasive cardiology, cardiac catheterization, arrhythmia/ECG, journal club, cardiology grand rounds, lipid management, research combined surgical/cardiac rounds and chief’s rounds. . For each lecture series, presentations include basic descriptions of the subspecialty as well as clinical discussions. Cardiology grand rounds consists of nationally recognized speakers discussing all relevant topics in cardiology. Once a month the fellows have the opportunity to meet with and present cases to an outside expert. In addition, the fellows undergo a 2-month course in cardiovascular diseases in July and August of each year. This course is designed to acquaint the incoming fellows with acute situations they may encounter as well as topics that may not be covered in other venues. EDUCATIONAL PROGRAM Clinical Cardiology Service: The Clinical Cardiology Service consists of both the Coronary Intensive Care Unit (CICU) and the Consultation Service. The concept is to provide a strong basis of clinical training for the fellow. Cardiac Intensive Care Unit Rotation: The primary responsibility of the cardiology fellow during a CICU rotation is to train and supervise medical students, interns and residents while overseeing the care of the patients in the CICU. Approximately 90-95% of patient admissions to the Cardiac Intensive Care Unit are done by private attending cardiologists. The remainder of patients are admitted to the Cardiology Fellow Service. The cardiology fellow, therefore, cares directly only for the fellow service patients and indirectly for the private cardiology patients by directing the care with house staff. In addition, the fellow helps to insert and troubleshoot Swan Ganz catheters as well as intra-aortic balloon pumps. Lastly, the cardiology fellow is responsible for all cardiac emergencies in the hospital during the CICU rotation, including being the code champion at cardiac alerts. Consultation Service: The Consultation Service at Hartford Hospital is responsible for all requests for cardiology consultations by in-hospital services. These services include internal medicine, surgery,
  5. 5. 5 obstetrics/gynecology, neurosurgery, etc. These consultations include such topics as preoperative evaluation, cardiac contusion, management of acute coronary syndromes, and congestive heart failure. The Cardiology Fellow in conjunction with the service attending evaluates all patients, performs physical examinations, and develops a diagnostic and management strategy. The attending physician with the Cardiology Fellow sees and evaluates all patients who undergoes cardiac consultation. In addition, the Cardiology Fellow is responsible the Chief’s Cardiology Service. These are admitted patients who have no assigned physician. Patients admitted to the Chief’s service carry such diagnoses as acute coronary syndrome, congestive heart failure, bacterial endocarditis, and other cardiovascular related illnesses. Outpatient Cardiovascular Clinic: An important part of the cardiovascular fellowship is the Outpatient Cardiovascular Clinic. Sessions are held Thursday and Friday afternoons on a weekly basis. Cardiovascular Fellows are assigned to one of these times and continue that time throughout the year. Unassigned patients who choose to receive services at the Brownstone Clinic are seen by Cardiology Fellows. These include patients with chronic stable angina, multiple valvular disorders, congestive heart failure, and arrhythmias. An attending physician is assigned to the clinic. The attending physician examines, and develops management strategies with the Cardiovascular Fellow. In addition to the unassigned patient, any recently hospitalized patient is followed in the Cardiovascular Clinic. Patients are also referred from the Internal Medicine Clinics seen in the same building. After an initial evaluation, the patients seen by the Cardiology Fellow may be followed for the duration of the Cardiovascular Fellow’s tenure. It is expected that the Cardiology Fellow will follow any patients from the Cardiovascular Clinic who are hospitalized. The fellow in conjunction with the Consultation/CICU fellow will assist in diagnostic and management decisions. The Outpatient Cardiovascular Clinic is a rich and rewarding part of the Cardiovascular Fellowship. This experience gives the Fellows long-term longitudinal exposure to further refine management strategies over time. Hartford Hospital is a primary and tertiary care center with referrals from the northern Connecticut area. Heart Rhythm Management/Interventional Electrophysiology Service: Heart Rhythm Management Services at Hartford Hospital consist of a diagnostic and interventional electrophysiology laboratories, Syncope Center, one of the largest device clinics in the region (8,000 encounters/year) and a busy consultation service. During the first year the fellow performs consultations in conjunction with the attending physician and assists in various studies such as electrophysiologic testing, tilt-table testing, holter monitoring and arrhythmia recognition. Fellows attend pacemaker and ICD clinics and learn device interrogation and programming. The heart rhythm management service is a busy one with over 1,000 consultations annually. EP studies and tilt-table tests are performed on a daily basis. Catheter ablation and biventricular pacing procedures are on the
  6. 6. 6 cutting edge of interventional electrophysiology. The goals of the first year are to become skilled at identification and treatment of arrhythmias, understand the role of electrophysiology and tilt studies and to perform device interrogation. The 2nd year fellow performs at least one month and possibly two months of advanced training and is expected to be more skilled in the evaluation of patients with arrhythmias as well as the performance of related procedures such as tilt-table testing, EPS, and assisting in catheter ablations. Cardiac Catheterization: Hartford Hospital has an active catheterization program. The facility consists of four adult cardiac catheterization suites equipped with digital x-ray systems. On an annual basis approximately 3700 procedures are performed including 1200 coronary interventional procedures. The patients who are referred to the laboratory represent a broad spectrum of cardiac pathology. The procedures offered include diagnostic cardiac catheterization, balloon angioplasty, coronary stent placement and the use of new and investigational devices. The vast majority of patients who present to Hartford Hospital with acute myocardial infarction are referred to the laboratory for primary intervention. The teaching faculty consists of seven cardiologists who are geographically based in the laboratory. Fellows in the first and second year of training are exposed to diagnostic right and left heart catheterization including coronary angiography. They participate in the pre-procedure evaluation of the patient and participate with the attending in the performance of the procedure and interpretation of results. The major emphasis in the first two years is acquiring knowledge of basic coronary anatomy and hemodynamics. Fellows in their third year can elect to spend nine months in the laboratory in order to obtain in-depth training in cardiac catheterization. Hartford Hospital also offers a dedicated fourth year of training in interventional cardiology, an ACGME approved program. In addition to clinical activities and teaching, the fellows have an opportunity to participate in the research activities of the laboratory. There is an active patient database that can be used for clinical research. The laboratory is involved with testing of new devices as part of clinical trials. There is also an animal facility for basic research. These activities have resulted in a number of presentations and publications by cardiology fellows. Echocardiography Laboratory: The Echocardiography Laboratory performs over 7,000 studies annually. Equipment includes state of the art Siemens and Phillips systems with emergency imaging performed 24 hours a day. The Echocardiography section provides comprehensive didactic and clinical training in the performance and interpretation of Echocardiograms. Training includes hands-on acquisition of transthoracic images with digital and tape storage and retrieval technology. The basics of ultrasound and Doppler physics are taught at length in didactic sessions. The fellow will become adept at performance and interpretation of complete
  7. 7. 7 transthoracic echocardiograms. Tools such as M-mode, second harmonic imaging, contrast echocardiography and power Doppler will be used on routine clinical examinations to enhance the diagnostic information obtained from the test. The first year fellow will spend 2 months in Echocardiography and will be expected to perform transthoracic echocardiograms on call with the assistance and backup of a Cardiac Sonographer and Attending. Research participation is encouraged. The objective of the first year in Echocardiography is to become adept at the utilization of echocardiography in clinical practice as a diagnostic tool. The second year fellow will continue with regularly scheduled didactic sessions reviewing the basic principles of Echocardiography. The fellow will continue to advance manual skills in the independent performance of transthoracic echocardiograms. The fellow will also be asked to regularly interpret complete transthoracic echocardiograms with a focus on providing a clinical diagnosis and a thorough interrogation of associated cardiac abnormalities. The objective of the second year in Echocardiography is to become adept at the independent performance and interpretation of complete transthoracic echocardiographic studies. The objective of the third year noninvasive Echocardiography program is to add procedural skills. The fellow will be trained in the performance of transesophageal and stress echocardiography (exercise treadmill and dobutamine stress). The fellow will continue active involvement in the didactic sessions and clinical performance and interpretation of transthoracic echocardiograms. The fellow who chooses the noninvasive path will spend 3-6 months in Echocardiography. A supplemental program is available for those who wish to sit for the ASE examination in Echocardiography. Nuclear Cardiology: The Nuclear Cardiology Laboratory is an integral part of the Cardiology Division and performs over 3,500 nuclear cardiology procedures annually. Equipment includes 3 dual head cameras on site and 3 satellite office locations as well as stress testing with oxygen consumption equipment. The Nuclear Cardiology Laboratory is part of the Cardiology Division and directed by a board certified nuclear cardiologist. Procedures include a myocardial perfusion imaging associated with gated-SPECT imaging, radionuclide ventriculography, shunt studies, myocardial infarct avid imaging as well as several experimental procedures with new radiopharmaceuticals in the development stages. The pharmacologic stress testing includes vasodilator stress with both dipyridamole and adenosine as well as inotropic stress with dobutamine. Cardiology fellows in the first and second year of training are exposed to four months of dedicated nuclear cardiology which afford them ample opportunity to perform exercise and pharmacology stress testing, and interpret nuclear cardiology procedures with an attending physician. The indications for the procedure as well as clinical implications of findings are discussed. A Non-Invasive conference shared by Echocardiography is held weekly. During the second year the fellow is expected to spend time with technologists to gain an understanding of image acquisition processing and quality control. Time is spent learning technical problems that can occur during the acquisition and processing of nuclear procedures. Fellows in the third year who opt
  8. 8. 8 to seek certification in nuclear cardiology may enroll in the University of Connecticut Nuclear Medicine Division Radiation Physics Course to gain certification of the 200 didactic hours required by the Nuclear Regulatory Commission. The third year fellow may gain enough participation for either Level 2 or Level 3 by ACC guidelines. The Level 3 accreditation requires one full year of participation in nuclear cardiology and allows the fellow to fully operate a nuclear cardiology laboratory. An optional fourth year of dedicated research is also possible. Preventive Cardiology: The Preventive Cardiology experience is integrated into the fellowship program with the concept that all well-trained cardiologists should know the principles of primary and secondary heart disease prevention. Preventive Cardiology includes the Cholesterol Management Center, the Nicotine Treatment Center, the Cardiac Rehabilitation Program, and the Exercise Research Program. First year fellows spend a one-month rotation in Preventive Cardiology. The fellow spends time in the Cholesterol Management Center addressing difficult lipid cases, attends smoking cessation clinic, and assists with Cardiac Rehabilitation. There are also didactic sessions provided to all fellows monthly to discuss preventive strategies. By the completion of the fellowship program, the fellow will know advanced lipid physiology, how the lipid lowering agents work, how to counsel patients in smoking cessation, the principles of exercise physiology and how they apply to active patients, and basic hypertension management. Research: The ACGME requires a minimum of 6 months research during the cardiovascular fellowship program. Each fellow is therefore expected to participate in active research projects during his/her fellowship period. Ample opportunity is provided for such experience beginning in the first year. Each year the fellow is expected to become more independent in his/her research but always with the guidance of a mentor. The research fellow is at liberty to choose any attending physician they wish for such guidance. The research environment at Hartford Hospital is extremely strong with participation in both independent and multi-center research projects. The fellows are encouraged to participate in independent research during the fellowship years. Funding is available if necessary through the Research Administration at Hartford Hospital. During the second and third years, if research has progressed, the fellow is encouraged to submit abstracts for the American Heart Association and American College of Cardiology meetings in addition subspecialty meeting applications are also possible. If accepted the fellow is expected to prepare the abstracts for presentation and move towards manuscript preparation. Recent publications by the Division of Cardiology are provided to demonstrate the productivity of the Division. The fellows’ progress is reviewed by a Residency Committee, which meets twice a year. In addition, the Program Director meets every 3 months with the fellow to discuss their evaluations by the attendings. The fellows’ research progress is also discussed during this time. The Program Director meets monthly with all fellows to discuss new information, problems and successes of the cardiovascular disease program.
  9. 9. 9 R e c e n t P u b l i c a t i o n s b y t h e C a r d i o l o g y D i v i s i o n Thompson PD, Tsongalis G, Ordovas JM, Seip RL, Bilbie C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N. Angiotensin-Converting Enzyme Genotype and Adherence to Aerobic Exercise Training. Preventive Cardiology, 9:21-4, 2006. Ouyang P, Tardif JC, Herrington DM, Stewart KJ, Thompson PD, Walsh MN, Bennett SK, Heldman AW, Tayback MA, Wang NY; for the Estrogen And Graft Atherosclerosis Research (EAGAR) investigators. Randomized trial of hormone therapy in women after coronary bypass surgery Evidence of differential effect of hormone therapy on angiographic progression of disease in saphenous vein grafts and native coronary arteries. Atherosclerosis. 189:375-86, 2006. Ruano G, Seip RL, Windemuth A, Zollner S, Tsongalis GJ, Ordovas J, Otvos J, Bilbie C, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N, Thompson PD.Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training. Atherosclerosis. 185:65-9, 2006. Blanchard BE, Tsongalis GJ, Guidry MA, LaBelle LA, Poulin M, Taylor AL, Maresh CM, Devaney J, Thompson PD, Pescatello LS. AAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension. Eur J Appl Physiol. 97:26-33, 2006. Clarkson PM, Kearns AK, Rouzier P, Rubin R, Thompson PD. Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc. 38:623-7, 2006. Cosio-Lima LM, Thompson PD, Reynolds KL, Headley SA, Winter CR, Manos T, Lagasse MA, Todorovich JR, Germain M. The acute effect of aerobic exercise on brachial artery endothelial function in renal transplant recipients. Prev Cardiol. 9:211-4, 2006. Syme AN, Blanchard BE, Guidry MA, Taylor AW, Vanheest JL, Hasson S, Thompson PD, Pescatello LS. Peak systolic blood pressure on a graded maximal exercise test and the blood pressure response to an acute bout of submaximal exercise. Am J Cardiol. 98:938-43, 2006. Seip RL, Otvos J, Bilbie C, Tsongalis GJ, Miles M, Zoeller R, Visich P, Gordon P, Angelopoulos TJ, Pescatello L, Moyna N, Thompson PD. The effect of apolipoprotein E genotype on serum lipoprotein particle response to exercise. Atherosclerosis. 188:126-33, 2006. Guidry MA, Blanchard BE, Thompson PD, Maresh CM, Seip RL, Taylor AL, Pescatello LS. The influence of short and long duration on the blood pressure response to an acute bout of dynamic exercise. Am Heart J. 151:1322.e5-12, 2006.
  10. 10. 10 Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller RF, Devaney JM, Hoffman EP. ACE ID genotype and the muscle strength and size response to unilateral resistance training. Med Sci Sports Exerc. 38:1074-81, 2006. Urso ML, Scrimgeour AG, Chen YW, Thompson PD, Clarkson PM. Analysis of human skeletal muscle after 48 h immobilization reveals alterations in mRNA and protein for extracellular matrix components. J Appl Physiol. 101:1136-48, 2006. Patel MD, Thompson PD. Phytosterols and vascular disease.Atherosclerosis. 186:12-9, 2006. Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis. Mar 16, 2006. Thompson PD, Clarkson PM, Rosenson RS; The National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 97:69C-76C, 2006. Roberts BH, Thompson PD. Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women? Gend Med. 3:5-12, 2006. Pelliccia A, Thompson PD. The genetics of left ventricular remodeling in competitive athletes. J Cardiovasc Med (Hagerstown). 7:267-70, 2006. Kapetanopoulos A, Kluger J, Maron BJ, Thompson PD. The congenital long QT syndrome and implications for young athletes. Med Sci Sports Exerc. 38:816-25, 2006. Baghdasarian SB, Thompson PD. How safe are very low LDL cholesterol levels? Nat Clin Pract Cardiovasc Med. 3:306-7, 2006. Ruffin R, Thompson PD. Can exercise prevent the common cold? Am J Med. 119:909, 2006. Fernandez A, Sorokin A, Thompson PD. Corneal arcus as coronary artery disease risk factor. Atherosclerosis. Oct 16, 2006. Thompson PD, Levine BD. Protecting athletes from sudden cardiac death. JAMA. 296:1648- 50, 2006. Williams PT, Thompson PD. Dose-dependent effects of training and detraining on weight in 6406 runners during 7.4 years. Obesity (Silver Spring). 2006 Nov;14(11):1975-84. Pescatello LS, Turner D, Rodriguez N, Blanchard BE, Tsongalis GJ, Maresh CM, Duffy V, Thompson PD. Dietary calcium intake and Renin Angiotensin System polymorphisms alter the blood pressure response to aerobic exercise: a randomized control design. Nutr Metab (Lond). 2007 Jan 4;4:1.
  11. 11. 11 Pistilli EE, Gordish-Dressman H, Seip RL, Devaney JM, Thompson PD, Price TB, Angelopoulos TJ, Clarkson PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Hoffman EP, Gordon PM. Resistin polymorphisms are associated with muscle, bone, and fat phenotypes in white men and women. Obesity (Silver Spring). 2007 Feb;15(2):392-402. Dornelas EA, Stepnowski RR, Fischer EH, Thompson PD. Urban ethnic minority women's attendance at health clinic vs. church based exercise programs. J Cross Cult Gerontol. 2007 Mar;22(1):129-36. Epub 2006 Nov 28. Thompson PD, Apple FS, Wu A. Marathoner's heart? Circulation. 2006 Nov 28;114(22):2306-8. Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis. 2007 Jan 19; [Epub ahead of print] John S, Sorokin AV, Thompson PD. Phytosterols and vascular disease. Curr Opin Lipidol. 2007 Feb;18(1):35-40. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM Jr, Krauss MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC; American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007 Mar 27;115(12):1643-455. Epub 2007 Mar 12. Dornelas EA, Thompson PD. Smoking cessation for cardiac patients. Prev Cardiol. 2007 Spring;10(2 Suppl 2):31-3. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A. Physical Activity and Public Health. Updated Recommendation for Adults From the American College of Sports Medicine and the American Heart Association. Circulation, Aug 2007. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 49:2231-7, 2007. Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 3rd, Fulton JE, Gordon NF, Haskell WL, Link MS, Maron BJ, Mittleman MA, Pelliccia A, Wenger NK, Willich SN, Costa F; American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American Heart Association Council on Clinical Cardiology; American College of Sports Medicine. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. 115:2358-68, 2007. Thompson PD. Cardiovascular adaptations to marathon running : the marathoner's heart. Sports Med. 37:444-7, 2007. Gadarla MR, Pullatt RC, Thompson PD. Role of Cardiac Rehabilitation after Acute Coronary Syndromes. Acute Coronary Syndromes. 8:49-55, 2007.
  12. 12. 12 Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 39:1423-34, 2007. Baggish AL, Thompson PD. The Athlete's Heart 2007: Diseases of the Coronary Circulation. Cardiol Clin. 25:431-40, 2007. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 9:389-96, 2007. Thompson PD, Estes III NAM. The Athlete’s Heart. In textbook of Cariovascular Medicine 3rd Edition ed. EJ Topol. Lippincott-Raven 686-697889-901, 2007. Bateman T, Heller GV, McGhie I, Friedman J, Case J, Bryngelson J, Hertenstein G, Moutray K, Reid K, Cullom SJ. Diagnostic Accuracy of Rest/Stress ECG-gated Rubidium-82 Myocardial Perfusion PET: Comparison with ECG-gated Tc-99m-Sestamibi SPECT. J Nucl Cardiol 2006;12:24-33. Papaioannou GI, Kasapis, C, Seip RL, Grey NJ, Katten D, Wackers FJ, Inzucchi SE, Engel S, Taylor A, Young LH, Chyun DA, Davey JA, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Heller GV. Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. J Nucl Cardiol 2006;13:362-8. Chyun DA, Melkus GD, Katten DM, Price WJ, Davey JA, Grey N, Heller GV, Wackers FJTh. The Association of Psychological Factors, Physical Activity, Neuropathy, and Quality of Life in Type 2 Diabetes. Biological Research for Nursing 2006, 7 (4):279-288. Shaw LJ, Heller GV, Casperson P, Miranda-Peats R, Slomka P, Friedman J, Hayes SW, Schwartz R, Weintraub WS, Maron DJ, Dada M, King S, Teo K, Hartigan P, Boden WE, O’Rourke RA, Berman DS. Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424. J Nucl Cardiol 2006;13:685-98. Singh, B, Bateman TM, Case JA, Heller GV. Attenuation artifact, attenuation correction, and the future of myocardial perfusion SPECT. J Nucl Cardiol 2007;14:153-64. Kapetanopoulos A, Ahlberg, AW, Taub C C, Katten DM, Heller GV. Regional Wall Motion Abnormalities on Post-Stress Electrocardiographic-Gated Tc-99mSestamibi Single-Photon Emission Computed Tomography Imaging Predict Cardiac Events. J Nucl Cardiol 2007;14:810-7. Wackers F J Th, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Resolution of Asymptomatic Myocardial Ischemia in Patients with Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study. Diabetes Care 2007;30:2892-2898.
  13. 13. 13 Shaw LJ, Berman DS, Maron DJ, Mancini J, Hayes SW, Hartigan PM, Weintraub WS, O’Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE. Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden (COURAGE). Circulation 2008;117:1283-1291. Ahlberg AW, Baghdasarian SB, Athar H, Thompsen JP, Katten DM, Noble GL, Mamkin I, Shah AR, Leka IA, Heller GV. Symptom-limited exercise combined with dipyridamole stress: Prognostic value in assessment of known or suspected coronary artery disease by use of gated SPECT Imaging. J Nucl Cardiol 2008;15:42-56. Heller GV, Katanick SL, Sloper T, Garcia M. Accreditation for Cardiovascular Imaging. JACC: Cardio Imaging 2008;1:390-7. Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, Heller GV. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol 2008 in press Venero CV, Heller GV, Bateman TM, McGhie AI, Ahlberg AW, Katten D, Courter S, Golub RJ, Case JA, Cullom SJ. Manuscript under review 2008 Bateman TM, Heller GV, McGhie AI, Courter SA, Golub RJ, Case JA, Cullom SJ. Multicenter Investigation Comparing a Highly Efficient Half-Time Stress-Only Attenuation Correction Approach (Astonish) Against Standard Rest-Stress Tc-99m SPECT Imaging. 2008 Under revision. Noble GL, Ahlberg AW, Kokkirala AR, Cullom SJ, Bateman TM, Cyr GM, Katten DM, Tadeo GD, Case JA, O’Sullivan DM, Heller GV. Validation of attenuation correction using transmission truncation compensation with a small field of view dedicated cardiac SPECT camera system. 2008 Under revision Mieres JH, Shaw LJ, Hendel RC, Heller GV. The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN? 2008 J Nucl Cardiol. In press. Baghdasarian SB, Heller GV. Patient preparation for nuclear imaging: When should anti- ischemic medications be withheld? J Nucl Cardiol 2007;14:775-81 Lertsburapa K, Heller GV. Infarct Sizing. 4th edition: Nuclear Cardiac Imaging: Principles and Applications. Editors: AE Iskandrian, Garcia EV 2008. Heller GV, Mann A, Hendel RC eds. Nuclear Cardiology: Technical Applications. McGraw-Hill 2008. Polk DM, Watson K. Hospital Discharge after an Acute Event: Evidence for a Systems Approach to Prevention. Coronary Artery Disease 2006;17(3):239-241. Kang K, Shaw LJ, Hayes SW, Hackamovitch R, Abidov A, Cohen I, Friedman JD, Thomson LE, Polk D, Germano G, Berman DS. Impact of body mass index on cardiac mortality in patients
  14. 14. 14 with known or suspected coronary artery disease undergoing myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 2006:47:1418-26. Wong ND, Gransar H, Shaw LJ, Polk D, Berman DS. Comparison of Atherosclerotic Calcification Burden in Persons with the Cardiometabolic Syndrome and Diabetes. JCMS 2006;1:90-94. Paul-Labrador M, Polk D, Dwyer JH, Velasquez I, Nidich S, Rainforth M, Schneider R, Bairey Merz CN. Effects of a Randomized Controlled Trial of Transcendental Meditation on Components of the Metabolic Syndrome in Subjects with Coronary Heart Disease. Arch Intern Med 2006;166:1218- 1224. Shaw LJ, Polk D, Merz CN. Assessing mature technology: what is the effect of high-quality risk stratification evidence with exercise echocardiography and single-photon emission computed tomography imaging? JACC. 2007;49(2):238-9. Berman DS, Shaw LJ, Hachamovitch R, Friedman JD, Polk DM, Hayes SW, Thompson LE, Germano G, Wong ND, Kang X, Rozanski A. Comparative use of radionuclide stress testing, coronary artery calcium scanning, and noninvasive coronary angiography for diagnostic and prognostic cardiac assessment. Seminars in Nuclear Medicine. 2007 37(1):2-16. Rozanski A, Gransar H, Wong ND, Shaw LJ, Miranda-Peats R, Polk D, Hayes SW, Friedman JD, Berman DS. Clinical Outcomes After Both Coronary Calcium Scanning and Exercise Myocardial Perfusion Scintigraphy. JACC. 2007;49:1352-1361. Polk D, Shah PK. Cholesterol ester transfer protein (CETP) and atherosclerosis. Drug Discovery Today: Therapeutic Strategies. 2007;4:137-145. White CM, Sander S, Coleman CI, Galagher R, Humphrey C, Henyan N, Gillespie EL, Kluger J. The Impact of epicardial anterior Fat Pad Retention on Post-Cardiothoracic Surgery Atrial Fibrillation incidence: The Atrial Fibrillation Supression Trial III (AFIST III). Submitted, Journal of the American College of Cardiology. 2007. 49(3):298-303. Baker W, White M, Kluger J, Denowtiz A, Konecny C, Coleman C. Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation length of stay. Heart Rhythm 2007 4(4): 461-468. Clyne CA, Shah A, Yarlagadda R, Migeed M, Kluger J. Catheter ablation for atrial fibrillation: Hartford Hospital experience. Conn Med. 2007 71(2): 69-67 Dale KM, Coleman CI Shah SA, Patel AA, Kluger J, White CM. Impact ` of gender on statin efficacy. Curr Med Res Opin. 2007 23(3): 565-74 White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg. 2007. 31(5): 818-21
  15. 15. 15 Shah SA, Sander S, Cios D, Lipeika J, Kluger J, White CM. Electrocardiographic and hemodynamic effects of coenzyme Q10 in healthy individuals: a double-blind, randomized controlled trial. Ann pharmacother. 2007. 41(3): 420-5 Coleman CI, Makanji S, Kluger J, White CM. Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation. Ann Pharmacother. 2007. 41(3) 433-7 Patel AA, Clyne CA, Henyan NN, Whiter CM, Zembrowski BF, Migeed M, Yarlagadda R, Kluger J, Coleman CI. The use of protamine after radiofrequency catheter ablation: A pilot study. J Interv Card Electrophysiol. 2007. Dale KM, Lertsburapa K, Kluger J, White CM. Moxifloxacin and torsade de pointes. Ann Pharmacother, 2007. 41(2):336-40 White CM, Sander S, Coleman CI, Gallagher R, Takata H, Humphrey C, Henyan N, Gillespie EL, Kluger J. Impact of epicardial anterior fat pad retention on postcardiothoracic surgery artial fibrillation incidence: the AFIST –III Study. J Am Coll Cardiol. 2007. 49(3):298-303 Coleman CI, Rigali VT, Hammond J, Kluger J, White CM. Evaluating the Safety Implications of Aprotinin Use: The Retrospective Evaluation of Aprotinin in CardioThoracic Surgery (REACTS). Submitted, JAMA. 148. Michael Gold, MD, PhD, FHRS, Jesus Val-Mejias, MD, Robert B. Leman, MD, Rangarao Tummala, MD, Sanjeev Goyal, MD, Jeffrey Kluger, MD, Mark Kroll, PhD, FHRS, Ashish Oza, MS. Optimization of superior vena cava coil position and usage for transvenous defibrillation. Heart Rhythm, March 2008. 5(3): 394-399 Brian F. McBride, PharmD, C. Michael white, PharmD, FCCP, FCP, James S, Kalus, PharmD, BCPS, Danette C. Guertin, MSN, APRN, Christopher A. Clyne , MD, William L. Baker, PharmD, BCPS, and Jeffrey Kluger, MD, FACC. The impact of carvedilol in the defibrillation threshold. Heart & Lung Vol. 37, No. 1 Feb, 2008 Gualberto Ruaño, James Bernene, Andreas Windemuth, Bruce Bower, Detlef Wencker, Richard L. Seip, Mohan Kocherla, Theodore R. Holford, William Petit, Stephen Hanks. (2008) Physiogenomic Comparison of Edema and BMI in Patients Receiving Rosiglitazone or Pioglitazone (Journal of Cardiac Failure, submitted) Detlef Wencker, Acute Cardio-Renal Syndrome: (2007) Progression from Congestive Heart Failure to Congestive Kidney Failure, Current Heart Failure Reports. 4(3), 134-138 Detlef Wencker, Joseph Feldschuh, Stuart D Katz. (2007) Optimization of Volume Status and Arterial Perfusion Pressure in Chronic Heart Failure: A Rational Approach Based on Direct Blood Volume Measurement. (European Journal of Heart Failure, submitted) Luisa F Durango, Stuart D Katz, Hung-Kei Li, Detlef Wencker. (2008) Continuous Furosemide Infusion is Safe and Effective in Outpatient Treatment of Refractory Heart Failure. (Circulation, in review).
  16. 16. 16 Luisa F Durango, Stuart D Katz, Hung-Kei Li, Detlef Wencker. (2006) Outpatient Treatment of Refractory Heart Failure with Intravenous Furosemide Infusion. J Cardiac Failure 6: S115. Dewland T, Wencker D, Androne AS, Hrniewiczk K, Katz SD. (2006) Clinical Correlates of Post- Exercise Heart Rate Recovery in Chronic Heart Failure. Journal of Cardiac Failure 6: S13 Carlos Mena, MD, Detlef Wencker, MD, Harlan M. Krumholz, MD, SM, Robert L. McNamara, MD. (2006). Detection Of Heart Transplant Rejection In Adults By Echocardiographic Diastolic Indices: A Quality Review Of The Literature, J Am Soc Echocardiogr. 2006 Oct;19(10):1295-300. Review Clyne CA, Athar H, Shah A, Kahr R, Rentas A. Thermal Mapping of Right Ventricular Outflow Tract Tachycardia. PACE, 2007 , March; 30(3): 343-51. Kapetanopolous A, Peckham G, Kiernan F, Clyne CA, Kluger J, Migeed M, Implantation of a biventricular pacing and defibrillator device via a persistant left superior vena cava. J Cardiovasc Med (Hagerstown). 2006 Jun;7(6):430-3 Clyne CA, Shah A, Yarlagadda R, Migeed M, Kluger J. Catheter Ablation for Atrial Fibrillation: Hartford Hospital Experience. Connecticut Medicine, 2007, February; 1 (2): 69-76. Patel A, Clyne CA, Henyan N, White M, Zembrowski B, Migeed M, Yarlagadda R, Kluger J, Coleman C. The use of protamine after radiofrequency catheter ablation: A pilot study. J Interv. Card. Electrophysiol. 2007, February ; 18(2):155-158. Patel AA, Clyne CA, Henyan NN, White CM, Zembrosky B, Migeed M, Yarlagadda R, Kluger J, Coleman CI. The Impact of Protamine on Thrombotic and Bleeding Complications in Patients Finishing Radiofrequency Catheter Ablation. Journal of Interventional Electrophysiology 2007: DOI: 10.1007/s10840-006-9063-z. Guertin D, Faheem O, Ling T, Pelletier G, McComas D, Yarlagadda R, Clyne C, Kluger J. Electromagnetic Interference (EMI) and arrhythmic events in ICD patients undergoing gastrointestinal procedures. Pacing Clin Electrophysiol. 2007, June; 30(6):734-9. McBride BF, White CM, Kalus J, Guertin D, Clyne C, Baker W, Kluger J. The Impact of Carvedilol on the Defibrillation Threshold. Heart & Lung 2008;37:67-71. Coleman C, Kluger J, Bhavnani S, Clyne C, Yarlagadda R, Guertin D, White M. Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction. Heart Rhythm. 2008, April 5(4) 507-510. Shah S, Clyne CA, Henyan N, Migeed M, Yarlagadda R, Silver B, Kluger J, White CM. The Impact of Magnesium Sulfate on Serum and Intracellular Magnesium Concentration Amongst Patients Undergoing Radio Frequency Catheter Ablation. Connecticut Medicine, May, 2008. Prgmde-2.doc